Alvotech And STADA Extend Partnership Through AVT03 Biosimilar Candidate Addition

6/11/24 4:17:36 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ALVO alert in real time by email

Under the terms of the agreement, Alvotech will be responsible for development and manufacturing at its state-of-the-art facility in Reykjavik, Iceland. STADA will become marketing authorization holder, upon approval of AVT03, and will assume semi-exclusive commercial rights in Europe, including Switzerland and the UK, as well as exclusive commercial rights in selected countries in Central Asia and the Middle East.

Get the next $ALVO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALVO

Date	Price Target	Rating	Analyst
1/29/2024	$10.00 → $17.00	Equal Weight → Overweight	Barclays
10/20/2023	$5.00 → $10.00	Sell → Neutral	Citigroup
9/21/2023	$10.00	Equal Weight	Barclays
9/7/2022	$10.00	Equal-Weight	Morgan Stanley
9/6/2022	$12.00 → $5.00	Buy → Sell	Citigroup

More analyst ratings

$ALVO
Press Releases

Fastest customizable press release news feed in the world

Alvotech Reports Financial Results for the First Nine Months of 2024
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine months of 2024 increased over four-fold compared to the same period last year, to $128 million, with Q3 product revenues contributing $62 millionLicense and other revenues for the first nine months of 2024 increased by $203 from the same period last year, to $211 million, with Q3 license and other revenues contributing $41 millionAdjusted EBITDA was $87 million in the first nine months of 2024, compared to negative ($225) million for the same period last year, with Q3 adjusted EBITDA contributi
11/13/24 4:05:00 PM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024
REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi's 2024 Global Healthcare Conference in Miami, Florida on December 4, 2024, and in Evercore's HealthCONx Conference in Coral Gables, Florida on December 5, 2024. Members of the management team will host one-on-one meetings at both conferences. Alvotech will also hold a fire-side chat at Evercore's HealthCONx Conference on Thursday, December 5, 2024 starting at 12:55 ET (17:55 GMT). A live audio webcast of Alvotech's fire-side chat at the Evercore He
11/7/24 8:00:00 AM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech's proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. This is believed to be the first marketing authorization application filing announced globally f
11/4/24 7:00:00 AM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ALVO
Market Insights

Live Market Insights

Barclays Maintains Overweight on Alvotech, Lowers Price Target to $18
Barclays analyst Balaji Prasad maintains Alvotech (NASDAQ:ALVO) with a Overweight and lowers the price target from $22 to $18.
7/25/24 8:23:02 AM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
STADA and Alvotech Launch Uzpruvo, First Stelara Biosimilar in Europe
STADA and Alvotech have launched Uzpruvo®, the first approved biosimilar to Stelara® in Europe, across a majority of European countries. This includes the largest markets in the region, where pricing and reimbursement approvals have been secured for market entry. The pioneering launch comes immediately upon expiry of exclusivity rights linked to the European reference molecule patent, offering patients, physicians and payers expanded access at the earliest possible opportunity to a life-altering medicine used in certain indications within gastroenterology1, dermatology and rheumatology. Launches in further European countries are scheduled over the coming months, following national price app
7/22/24 6:36:42 AM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Alvotech Announces Topline Results From Confirmatory Patient Study For AVT03, A Proposed Biosimilar For Prolia and Xgeva
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endpoint Alvotech expects to file marketing applications for AVT03 later this year for major global markets REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a confirmatory patient study for AVT03, a proposed biosimilar to Prolia® (den
7/2/24 9:13:41 AM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Alvotech Reports Financial Results for the First Nine Months of 2024
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine months of 2024 increased over four-fold compared to the same period last year, to $128 million, with Q3 product revenues contributing $62 millionLicense and other revenues for the first nine months of 2024 increased by $203 from the same period last year, to $211 million, with Q3 license and other revenues contributing $41 millionAdjusted EBITDA was $87 million in the first nine months of 2024, compared to negative ($225) million for the same period last year, with Q3 adjusted EBITDA contributi
11/13/24 4:05:00 PM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
REYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of the year ended September 30, 2024, after U.S. markets close on Wednesday, November 13, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Thursday November 14, 2024, at 8:00 am ET (13:00 GMT). Live audio of the conference call will also be webcast and available to members of the news media, investors, and the general public. Access information is posted on Alvotech's
10/30/24 8:30:00 AM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023 Product revenues for the first six months were $66 million, a 190% increase from the same period last year, with Q2 product revenues contributing $53 million License and other revenues for the first six months increased to $170 million, with Q2 license and other revenues contributing $145 million Adjusted EBITDA in the first six months was $64 million, compared to negative ($147) million for the same period last year, with Q2 adjusted EBITDA contributing $102 million Achieved numerous development and perf
8/15/24 4:15:00 PM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ALVO
Leadership Updates

Live Leadership Updates

Alvotech Appoints Interim Chief Quality Officer
REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY, most recently as Alvogen's Chief Quality Officer. "We thank Sandra for her valuable contribution to Alvotech, as she successfully steered ou
2/29/24 4:05:00 PM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biodexa Appoints Ann Merchant to the Board of Directors
Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa
12/29/23 4:05:00 AM ET
$ALVO
$BDRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Alvotech Appoints Sarah Tanksley as Chief Quality Officer
REYKJAVIK, Iceland, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its corporate leadership team as Chief Quality Officer, effective October 14. Ms. Tanksley succeeds Reem Malki, who is stepping down for personal reasons. "Sarah has been actively working with Alvotech as a consultant and we are very pleased that she will join our team in this new capacity," said Mark Levick, Chief Executive Officer of Alvotech. "Her familiarity with our operation facilitates a smooth transition and we are excited to benefit furt
10/11/22 5:00:00 PM ET
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Alvotech And STADA Extend Partnership Through AVT03 Biosimilar Candidate Addition

Chat with this insight

Recent Analyst Ratings for $ALVO

$ALVO SEC Filings

SEC Form 6-K filed by Alvotech

SEC Form 6-K filed by Alvotech

SEC Form 6-K filed by Alvotech

$ALVO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Alvotech upgraded by Barclays with a new price target

Alvotech upgraded by Citigroup with a new price target

Barclays initiated coverage on Alvotech with a new price target

$ALVO Press Releases

Fastest customizable press release news feed in the world

Alvotech Reports Financial Results for the First Nine Months of 2024

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

$ALVO Market Insights

Live Market Insights

Barclays Maintains Overweight on Alvotech, Lowers Price Target to $18

STADA and Alvotech Launch Uzpruvo, First Stelara Biosimilar in Europe

Alvotech Announces Topline Results From Confirmatory Patient Study For AVT03, A Proposed Biosimilar For Prolia and Xgeva

$ALVO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Alvotech

Amendment: SEC Form SC 13D/A filed by Alvotech

SEC Form SC 13G/A filed by Alvotech (Amendment)

$ALVO FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$ALVO Financials

Live finance-specific insights

FDA Approval for SELARSDI issued to ALVOTECH USA INC

FDA Approval for SELARSDI issued to ALVOTECH USA INC

FDA Approval for SELARSDI issued to ALVOTECH USA INC

Alvotech Reports Financial Results for the First Nine Months of 2024

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

$ALVO Leadership Updates

Live Leadership Updates

Alvotech Appoints Interim Chief Quality Officer

Biodexa Appoints Ann Merchant to the Board of Directors

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

Recent Analyst Ratings for
$ALVO

$ALVO
SEC Filings

$ALVO
Analyst Ratings

$ALVO
Press Releases

$ALVO
Market Insights

$ALVO
Large Ownership Changes

$ALVO
FDA approvals

$ALVO
Financials

$ALVO
Leadership Updates